Four weeks after the tumor challenge, we analyzed tumor tissues from MiaPaCa-2/CTHRC1 cell-injected mice for cells positive for CD45, a general lymphohematopoietic cell marker, and CD31, an EC marker, by immunofluorescence. This evidence concerns the gene PTPRC and neoplasm.